Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
Agenus reported a strong financial turnaround in Q1 2026 with $33.7 million in revenue and net income of $39.2 million, driven largely by the Zydus collaboration which delivered $91 million in upfront capital and secured U.S. manufacturing capacity. Operationally, the lead program BOT+BAL advanced into Phase 3 enrollment with the BATTMAN trial, while the SEC investigation concluded without recommended enforcement action and related securities class action was dismissed.
Key figures
- Revenue
- $33.7 million
- Guidance
- Annualized operating expenses expected to be approximately $50 million
- Net income
- 39200000
- Revenue Yoy
- 39.8%
- Operating income
- 15100000
- Deal equity
- 16000000
- Atm proceeds
- 11700000
- Deal upfront
- 91000000
- Cash position
- 35000000
- Royalty revenue
- 29100000
- Deal contingent max
- 50000000
- Pre commercial revenue
- 4600000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.